Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

h the use of nucleoside analogues alone or in combination with other antiretrovirals. Viread is not approved for the treatment of chronic hepatitis B and the safety and efficacy of Viread have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Viread. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of Viread. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy with Viread and as clinically appropriate during therapy. Coadministration of Viread and didanosine should be undertaken with caution. Patients should be monitored closely for didanosine-associated adverse events, and didanosine should be discontinued if these occur. Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, and Viread should be discontinued if these occur. When co-administered with Viread, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg. Atazanavir without ritonavir should not be co-administered with Viread.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been seen with the use of Viread. The effects of Viread-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Changes in body fat have been observed in patients taking anti-HIV medicines. The cause and long-term health effect of these changes are unknown. Immune Reconstitution Syndrome has been reported in patients treated with combination therapy, including Viread.

The m
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:9/23/2014)... PARIS , September 23, 2014 /PRNewswire/ ... tels que l,automobile, la santé, le ferroviaire ... en plus connectées, donneront progressivement accès à ... issues des nombreux capteurs installés au cœur ... estime à plusieurs dizaines de milliards le ...
(Date:9/23/2014)... Fla. and DUBLIN ... (OTC-BB: TNIB) ("we" or the "Company"), a biotechnology ... therapies for autoimmune diseases in emerging nations, today ... approved our common stock for DTC,s Deposit and ... Automated Securities Transfer Service ("FAST") transfer agent as ...
(Date:9/23/2014)... The Pennsylvania State Police will accept unwanted, expired ... of National Prescription Drug Take-Back Day. The service is ... Day is a national initiative, conducted in partnership with ... the public to dispose of expired, unused or unwanted ... From 10 a.m. to 2 p.m., unwanted ...
Breaking Medicine Technology:Altran transforme le big data du monde industriel en nouveau business 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... needle-free vaccine,platform that elicits a robust immune response ... been awarded a U.S. patent. The University of,Michigan ... from the,university, licenses the patent and its associated ... nanoemulsion,technology, have elicited a dramatic immune response in ...
... Inc.,(Nasdaq: NUVO ) today announced that it ... 1 trial to determine the safety, tolerability and,pharmacokinetics ... approximately 30 healthy male volunteers., "This proof-of-concept ... to achieve rapid onset and offset of anticoagulation," ...
Cached Medicine Technology:New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity 2New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity 3Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172 2Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172 3
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all ... it can be treated. , A medically retired Army ... His platoon sustained multiple attacks resulting in five casualties. ... combat-related PTSD and honorably discharged from the Army. , ... distanced myself from my friends and family,” recalled O’Farrell, ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 ... for providing better care, not more ... choices. A new report suggests that,s the direction ... the IMS Institute for Healthcare Informatics in Parsippany, N.J., identifies ... the delivery of health care and use of medicines over ...
(Date:9/23/2014)... September 23, 2014 What information ... The National Quality Forum (NQF) released a report ... ), and an infographic ( http://bit.ly/1tX3lzA ) resulting ... of healthcare, how patients define affordability, and what ... get the best possible healthcare at the lowest ...
(Date:9/23/2014)... CORVALLIS, Ore. A recent Oregon survey about an ... into the daily routine of elementary school students found ... students and teachers, and offered clear advantages for overly ... was developed and produced by the Healthy Youth Program ... and is available nationally. , Brain Breaks leads children ...
(Date:9/23/2014)... 2014 Trevera provides multiple lines ... are Oracle Managed Services , Oracle Solutions ... versions of Oracle E-Business Databases and Applications, ... Trevera has announced a significant enhancement to its ... with their software technology management, project management, governance, ...
Breaking Medicine News(10 mins):Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay ... Monday,s decision by a U.S. judge to halt ... The temporary injunction, which basically blindsided the scientific ... the pre-2001 days. That was when then-President Bush ordered ...
... people lose weight and body fat when they exercise and eat ... (MR) spectroscopy can provide the answer and help predict who ... online and will appear in the November issue of the journal ... the same and have the same body mass index (BMI), but ...
... By Kathleen Doheny HealthDay Reporter , TUESDAY, Aug. ... sweetened, carbonated diet sodas a day boost a woman,s odds ... suggests such a link. The researchers looked at the ... a national study there from 1996 to 2002. The ...
... Aug. 24, 2010 The Joint Commission has ... a Primary Stroke Center, a distinction for hospitals fostering ... teams of neurologists, imaging specialists, nurses and technicians have ... limit damage during or after a stroke. Each year ...
... exams may increase a woman,s risk of developing radiation-induced ... in the October issue of Radiology . However, ... low. "A single breast-specific gamma imaging (BSGI) or ... of inducing fatal cancer greater than or comparable to ...
... success is surely sweeter than failure, it seems failure is ... flourish more in the long run, according to a ... the University of Colorado Denver Business School. Desai,s research, ... on companies and organizations that launch satellites, rockets and shuttles ...
Cached Medicine News:Health News:Scientists Dismayed by Stem Cell Research Ruling 2Health News:Scientists Dismayed by Stem Cell Research Ruling 3Health News:Fat distribution plays a role in weight loss success in patients at risk of diabetes 2Health News:Study Suggests Link Between Diet Sodas, Preterm Delivery 2Health News:Study Suggests Link Between Diet Sodas, Preterm Delivery 3Health News:UT Southwestern University Hospital -- St. Paul recognized as Primary Stroke Center 2Health News:UT Southwestern University Hospital -- St. Paul recognized as Primary Stroke Center 3Health News:New nuclear breast imaging technologies associated with higher cancer risks 2Health News:New nuclear breast imaging technologies associated with higher cancer risks 3Health News:University of Colorado Denver Business School study shows failure better teacher than success 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: